Core protocol development for phase 2/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates

[1]  V. L. Schermer,et al.  Book Review: Ruptures in the American Psyche: Containing Destructive Populism in Perilous Times , 2022, Group Analysis.

[2]  M. S. van der Knaap,et al.  Guanabenz ameliorates disease in vanishing white matter mice in contrast to sephin1 , 2022, Annals of clinical and translational neurology.

[3]  M. Patterson,et al.  Lost in translation—Challenges in drug development for inherited metabolic diseases , 2022, Journal of inherited metabolic disease.

[4]  Robert M. Rauner,et al.  Therapy Trial Design in Vanishing White Matter , 2022, Neurology: Genetics.

[5]  S. Paganoni,et al.  Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development , 2021, Annals of neurology.

[6]  C. Teunissen,et al.  Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy , 2021, Brain : a journal of neurology.

[7]  F. Barkhof,et al.  MRI Natural History of the Leukodystrophy Vanishing White Matter. , 2021, Radiology.

[8]  P. Bycott,et al.  Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials , 2021, Therapeutic Innovation & Regulatory Science.

[9]  S. de Lusignan,et al.  Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk , 2021, BMJ Open.

[10]  A. Gelman,et al.  Bayesian statistics and modelling , 2021, Nature Reviews Methods Primers.

[11]  I. D. de Esch,et al.  Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations , 2021, Molecular genetics & genomic medicine.

[12]  M. Langeveld,et al.  Registries for orphan drugs: generating evidence or marketing tools? , 2020, Orphanet Journal of Rare Diseases.

[13]  P. Bayrak-Toydemir,et al.  Elevated Leukodystrophy Incidence Predicted From Genomics Databases. , 2020, Pediatric neurology.

[14]  Jay J H Park,et al.  An Overview of Platform Trials with a Checklist for Clinical Readers. , 2020, Journal of clinical epidemiology.

[15]  C. M. W. Gaasterland,et al.  Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation , 2019, BMC Medical Research Methodology.

[16]  S. van der Sluis,et al.  Vanishing white matter: deregulated integrated stress response as therapy target , 2019, Annals of clinical and translational neurology.

[17]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[18]  A. Hrõbjartsson,et al.  Randomized clinical trials with run-in periods: frequency, characteristics and reporting , 2019, Clinical epidemiology.

[19]  J. H. van der Lee,et al.  The patient’s view on rare disease trial design – a qualitative study , 2019, Orphanet Journal of Rare Diseases.

[20]  H. D. de Vet,et al.  Natural History of Vanishing White Matter , 2018, Annals of neurology.

[21]  V. Heine,et al.  Bergmann glia translocation: a new disease marker for vanishing white matter identifies therapeutic effects of Guanabenz treatment , 2018, Neuropathology and applied neurobiology.

[22]  Brian M Alexander,et al.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE , 2017, Clinical Cancer Research.

[23]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[24]  M. Nieto‐Sampedro,et al.  Integrated Stress Response as a Therapeutic Target for CNS Injuries , 2017, BioMed research international.

[25]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[26]  D. Bolignano,et al.  Good-quality research in rare diseases: trials and tribulations , 2016, Pediatric Nephrology.

[27]  R. Hagendijk,et al.  Post-authorisation assessment of orphan drugs , 2015, The Lancet.

[28]  Anna M. McGeachy,et al.  The small molecule ISRIB reverses the effects of eIF2α phosphorylation on translation and stress granule assembly , 2015, eLife.

[29]  Joshua J Gagne,et al.  Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.

[30]  C. Bouwmans,et al.  IMTA Productivity Cost Questionnaire (IPCQ). , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  S. Groeschel,et al.  Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort , 2014, Orphanet Journal of Rare Diseases.

[32]  F. Eichler,et al.  Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A Systematic Review of the Literature , 2014, Neuropediatrics.

[33]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[34]  H. Prange,et al.  „Vanishing white matter disease“ , 2011, Der Nervenarzt.

[35]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[36]  I. Krägeloh-Mann,et al.  Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy , 2011, Developmental medicine and child neurology.

[37]  B. Tatlı,et al.  Genotype–phenotype correlation in vanishing white matter disease , 2010, Neurology.

[38]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.

[39]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[40]  M. Parmar,et al.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial , 2009, Trials.

[41]  A. Eliasson,et al.  The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. , 2006, Developmental medicine and child neurology.

[42]  J. Varni,et al.  The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 children , 2005, Expert review of pharmacoeconomics & outcomes research.

[43]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[44]  H. Moser,et al.  Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. , 2004, Blood.

[45]  E. Bertini,et al.  The effect of genotype on the natural history of eIF2B-related leukodystrophies , 2004, Neurology.

[46]  D. Feeny,et al.  The Health Utilities Index (HUI®): concepts, measurement properties and applications , 2003, Health and quality of life outcomes.

[47]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[48]  Rune R. Frants,et al.  Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter , 2001, Nature Genetics.

[49]  J. Varni,et al.  The PedsQL: measurement model for the pediatric quality of life inventory. , 1999, Medical care.

[50]  R. Palisano,et al.  Development and reliability of a system to classify gross motor function in children with cerebral palsy , 1997, Developmental medicine and child neurology.

[51]  N. Silberberg,et al.  Hand strength and dexterity. , 1971, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[52]  Cesare Cornoldi,et al.  Leiter-3 Leiter International Performance Scale Tirth Edition. Standardizzazione italiana , 2016 .

[53]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[54]  Tom Lodewyckx,et al.  Bayesian Versus Frequentist Inference , 2008 .

[55]  H. Hoijtink,et al.  Bayesian Evaluation of Informative Hypotheses. , 2008 .

[56]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[57]  D. Wade,et al.  Mobility after stroke: reliability of measures of impairment and disability. , 1990, International disability studies.